Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | STAT6 | P42226 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL1321676 | 1.00 | SLC29A1 (1.00) | SLC29A1CYP3A4TP53HIF1AABCC4 | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL7617534 | 1.00 | SLC29A1 (1.00) | SLC29A1CYP3A4TP53HIF1AABCC4 | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL29374837 | 1.00 | SLC29A1 (1.00) | SLC29A1CYP3A4TP53HIF1AABCC4 | |
| SCHEMBL1763081 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4TP53HIF1AABCC4 | |
| SCHEMBL29784689 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4TP53HIF1AABCC4 | |
| SCHEMBL20579724 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4TP53HIF1AABCC4 | |
| SCHEMBL1322160 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4TP53HIF1AABCC4 | |
| 6-Benzylthioinosine SCHEMBL7617372 | 0.86 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| 6-Benzylthioinosine SCHEMBL15427008 | 0.86 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| 6-Benzylthioinosine SCHEMBL7617380 | 0.86 | SLC29A1 (1.00) | SLC29A1STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190282580-A1 | PRO-INFLAMMATORY ROLE FOR ADENOSINE UPTAKE AND METABOLISM | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY | 2019-09-19 | — | — | US | claimed |
| US-20190209598-A1 | USE OF A DHODH INHIBITOR IN COMBINATION WITH AN INHIBITOR OF PYRIMIDINE SALVAGE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-07-11 | — | — | US | claimed |
| US-20190125779-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-05-02 | — | — | US | claimed |
| WO-2018089835-A1 | A PRO-INFLAMMATORY ROLE FOR ADENOSINE UPTAKE AND METABOLISM | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2018-05-17 | — | — | WO | claimed |
| US-20180008540-A1 | UNIT AEROSOL DOSES FOR ANTICOAGULATION | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-01-11 | — | — | US | claimed |
| EP-3247332-A1 | UNIT AEROSOL DOSES FOR ANTICOAGULATION | Incarda Therapeutics, Inc. (US) | 2017-11-29 | — | — | EP | claimed |
| WO-2017117006-A1 | USE OF A DHODH INHIBITOR IN COMBINATION WITH AN INHIBITOR OF PYRIMIDINE SALVAGE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-07-06 | — | — | WO | claimed |
| US-20170042929-A9 | Methods of Treating Neurological Diseases | UNIVERSITY OF HOUSTON | 2017-02-16 | — | — | US | claimed |
| WO-2016118625-A1 | UNIT AEROSOL DOSES FOR ANTICOAGULATION | INCARDA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | WO | claimed |
| WO-2016109624-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-07-07 | — | — | WO | claimed |
| WO-1996028163-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1996-09-19 | — | — | WO | claimed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | claimed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| WO-1994023723-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE PROMOTION OF WOUND HEALING | NEW YORK UNIVERSITY (US) | 1994-10-27 | — | — | WO | claimed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| EP-0416011-A4 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | US COMMERCE (US) | 1991-05-22 | — | — | EP | claimed |
| EP-0416011-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1991-03-13 | — | — | EP | claimed |
| WO-1989011274-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-11-30 | — | — | WO | claimed |
| WO-1989010122-A1 | COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS HYPERPROLIFERATIVE DISORDERS | YALE UNIVERSITY (US) | 1989-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209598-A1 | USE OF A DHODH INHIBITOR IN COMBINATION WITH AN INHIBITOR OF PYRIMIDINE SALVAGE | DHODH, DPYD, DHPS | SLC29A1 138/4885CYP3A4 705/4885TP53 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.